CONSHOHOCKEN, PA--(Marketwire - Feb 29, 2012) - NuPathe Inc. (NASDAQ: [ PATH ]), a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that [ Jane Hollingsworth ], chief executive officer, will present a company overview at Cowen and Company 32^nd Annual Health Care Conference on Wednesday, March 7, 2012, at 8:00 a.m. EST. The conference is being held at the Boston Marriott Copley Place in Boston, MA.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe's website for 90 days following the presentation.

About NuPathe
[ NuPathe ] Inc. is a biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, [ NP101 ], is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder. For more information, please visit our website and our blog at [ www.nupathe.com ]. You can also follow us on StockTwits ([ http://stocktwits.com/NuPatheIR ]), Twitter ([ https://twitter.com/#!/NuPathe ]), SlideShare ([ http://www.slideshare.net/NuPathe ]), and LinkedIn ([ http://www.linkedin.com/company/146880 ]).